

CITATION REPORT

List of articles citing

Adverse prognostic significance of new diabetes in treated hypertensive subjects

DOI: 10.1161/01.hyp.0000125726.92964.ab
Hypertension, 2004, 43, 963-9.

Source: <https://exaly.com/paper-pdf/36705042/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
458	When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. <i>Hypertension</i> , 2004 , 43, 941-2	8.5	20
457	Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. 2004 , 22, 1867-8		5
456	Metabolic syndrome and other factors associated with increased risk of diabetes. 2004 , 6 Suppl 3, S14-29		6
455	Hypertension and the metabolic syndrome. 2004 , 6, 427-33		6
454	Hypertension in the elderly. 2004 , 6, 469-76		8
453	Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects. 2004 , 6, 365-6		3
452	Relationship between antihypertensive drugs and metabolic syndrome. 2004 , 2, 308-14		2
451	Los diuréticos son los fármacos de primera elección en el tratamiento de la hipertensión arterial. 2004 , 21, 466-474		
450	¿Deben ser considerados los diuréticos como fármacos de uso prácticamente exclusivo en el tratamiento inicial del hipertenso?. 2004 , 21, 475-481		
449	Cardiovascular therapies and risk for development of diabetes. 2004 , 44, 509-12		52
448	The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. 2004 , 17, 16S-20S; quiz A2-4		99
447	Insights into the biology of diabetic vascular disease: what's new?. 2004 , 17, 2S-6S; quiz A2-4		36
446	Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?. 2004 , 6, 425-7		10
445	Diuretic-related side effects: development and treatment. 2004 , 6, 532-40		66
444	New-onset diabetes in the hypertension treatment trials: a point of view. 2004 , 6, 610-3		14
443	Recommendations for Special Populations. 2004 , 14, 368-381		7
442	Antihypertensive therapy and new onset diabetes. 2004 , 22, 1845-7		48

441	Never mind the quality, feel the width--ALLHAT revisited. 2004 , 13, 330-4	5
440	Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. 2005 , 329, 292-305	64
439	Guidelines for Antihypertensive Treatment: The Debate on the Choice of Antihypertensive Drugs. 2005 , 53-61	
438	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 14, 435-41	28
437	NADPH oxidase, superoxide overproduction and nitric oxide bioavailability in essential hypertension. 2005 , 23, 665-6	6
436	Diuretics and new onset diabetes: is it a problem?. 2005 , 23, 666-8; author reply 668-9	2
435	The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. 2005 , 23, 1777-81	76
434	Do we need to target 'prediabetic' hypertensive patients?. 2005 , 23, 2119-25	10
433	Reducing cardiovascular disease in patients with diabetes mellitus. 2005 , 20, 245-9	8
432	Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. 2005 , 23, 463-73	225
431	Diuretics and new onset diabetes: is it a problem?. 2005 , 23, 668-669	2
430	Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. 2005 , 23, 669-70; author reply 670-1	5
429	Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. 2005 , 23, 670-671	
428	Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression?. 2005 , 14, 448-52	10
427	Bibliography Current World Literature. 2005 , 20, 324-368	
426	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 4, 469-475	
425	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 4, 583-589	
424	Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. 2005 , 19, 331-9	41

423	Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. 2005 , 59, 632-8	10
422	Hipertensi3 arterial y riesgo cardiovascular en el a3 2004. 2005 , 5, 24A-34A	
421	Hipertensi3 arterial y s3ndrome metab3lico. 2005 , 5, 38D-45D	1
420	New-onset diabetes in treated hypertensive patients. 2005 , 7, 174-9	27
419	Differential effects of antihypertensive drugs on new-onset diabetes?. 2005 , 7, 249-56	22
418	Angiotensin II-receptor antagonist in the treatment of hypertension. 2005 , 7, 287-93	6
417	Antihypertensive treatment and new-onset diabetes mellitus. 2005 , 7, 298-303	16
416	Role of hypertension in the metabolic syndrome: who is affected?. 2005 , 7, 418-26	6
415	Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. 2005 , 7, 314-22	20
414	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2005 , 340-351	
413	Hypertension guidelines, meta-analyses and clinical trials: do we assume too much?. 2005 , 182, 82-4	5
412	Calcium antagonists: effects on cardio-renal risk in hypertensive patients. <i>Hypertension</i> , 2005 , 46, 637-428.5	56
411	Angiotensin-receptor blockers and diuretics--advantages of combination. 2005 , 14, 6-11	13
410	Should a diuretic always be the first choice in patients with essential hypertension? The case for no. 2005 , 16 Suppl 1, S70-3	15
409	Diabetic brain damage in hypertension: role of renin-angiotensin system. <i>Hypertension</i> , 2005 , 45, 887-938.5	52
408	Hypertension 2005: an evidence-based approach to diagnosis and treatment - an American perspective. 2005 , 3, 691-704	4
407	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 2005 , 10, 729-45	7
406	Improving Antihypertensive Agent Selection to Promote Nephroprotection. <i>Current Hypertension Reviews</i> , 2005 , 1, 141-157	2.3

405	Evidence that new antihypertensives are superior to older drugs. 2005 , 366, 869-71	65
404	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. 2005 , 366, 895-906	2253
403	Papel de los ARA-II en el tratamiento de la hipertensi3n arterial. De la evidencia a la pr3ctica cl3nica. 2005 , 17, 70-82	
402	Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial. 2005 , 7, 132-9	12
401	Integrated management of patients with diabetes mellitus and ischemic heart disease: PCI, CABG, and medical therapy. 2005 , 30, 583-617	2
400	[ARB II in chronic heart failure. Coincidences and divergences. Class effect?]. 2005 , 205, 499-506	
399	Therapeutic controversies in hypertension. 2005 , 25, 227-35	6
398	The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. 2005 , 6, 275-81	8
397	Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. 2005 , 5, 171-83	36
396	Treating Hypertension with Angiotensin II Receptor Blockers. 2005 , 12, 9-15	2
395	Benefits of Diuretic-Based Low-Cost Antihypertensive Therapy. 2005 , 12, 73-78	
394	What Should We Expect from the Next Guidelines on Hypertension?. 2005 , 12, 199-202	
393	Development of diabetes with thiazide diuretics: the potassium issue. 2005 , 7, 638-40	9
392	Treating stage 2 hypertension. 2005 , 7, 464-70	3
391	Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. 2005 , 7, 669-78	12
390	The ASCOT trial. 2005 , 7, 748-50	5
389	Can type 2 diabetes mellitus be considered preventable?. 2005 , 68 Suppl1, S73-81	21
388	Hypertension: a review and rationale of treatment. 2005 , 51, 548-614	8

387	The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. 2005 , 18, 100S-105S		17
386	Update on the drug treatment of hypertension in patients with cardiovascular disease. 2005 , 118, 695-705		21
385	Recent hypertension trials: implications and controversies. 2005 , 45, 813-27		95
384	Clinical pharmacology of antihypertensive therapy. 2005 , 25, 215-26		6
383	Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII. 2005 , 34, 63-75		20
382	The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. 2006 , 23, 131-55		28
381	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 28, 1462-536		1418
380	The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?. 2006 , 6, 139-47		15
379	Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. 2006 , 6, 189-208		26
378	Management issues in hypertensive diabetics. 2006 , 48, 38-40		
377	Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. <i>Hypertension</i> , 2006 , 48, 219-24	8.5	349
376	Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?. <i>Hypertension</i> , 2006 , 48, 198-200	8.5	33
375	Antihypertensive medications and blood sugar: theories and implications. 2006 , 22, 229-33		30
374	Hipertensi3 arterial y s3ndrome metab3lico. 2006 , 23, 19-27		2
373	Influencia de la prediabetes en el pron3stico cardiovascular del paciente hipertenso. 2006 , 23, 86-92		
372	3ltimas novedades en hipertensi3. Congreso Americano de Hipertensi3 Arterial 2006. 2006 , 23, 146-151		
371	¿Los hallazgos del estudio STAR (the Study of Trandolapril/Verapamil-SR and Insulin Resistance) cambiar3 el tratamiento de los pacientes hipertensos con el s3ndrome metab3lico?. 2006 , 23, 241-243		
370	ASCOT-BPLA - Authors' reply. 2006 , 367, 207-208		1

369	What is the role of angiotensin-receptor blockade in cardiovascular protection?. 2006 , 152, 859.e1-8	4
368	Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. 2006 , 19, 189-96; discussion 197-8	56
367	¿Los hallazgos del estudio STAR (the Study of Trandolapril/Verapamil-SR and Insulin Resistance) cambiarían el tratamiento de los pacientes hipertensos con el síndrome metabólico?. 2006 , 23, 241-243	
366	Risk of diabetes in patients taking thiazide diuretics. 2006 , 81, 1637-8; author reply 1638	2
365	Últimas novedades en hipertensión. Congreso Americano de Hipertensión Arterial 2006. 2006 , 23, 146-151	
364	Effect of antihypertensive agents on the development of type 2 diabetes mellitus. 2006 , 81, 796-806	47
363	Hipertensión arterial y síndrome metabólico. 2006 , 23, 19-27	
362	ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. 2006 , 66, 1169-77	17
361	Metabolismo glucídico en la hipertensión arterial: papel de la sobrecarga oral de la glucosa. 2006 , 126, 116	0
360	[Abnormal glycemic metabolism in essential hypertension. Role of the oral glucose tolerance test]. 2006 , 126, 116-7; author reply 117	
359	[Prevalence of metabolic syndrome and association with ischemic heart disease in cardiological outpatients]. 2006 , 206, 259-65	5
358	[Is essential hypertension essentially metabolic?]. 2006 , 127, 705-8	
357	Predictors of adverse outcome among patients with hypertension and coronary artery disease. 2006 , 47, 547-51	42
356	Directly measured insulin resistance and the assessment of clustered cardiovascular risks in hypertension. 2006 , 19, 1118-24	9
355	Glucose metabolism in patients with essential hypertension. 2006 , 119, 318-26	85
354	Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). 2006 , 151, 1072-9	55
353	Is new-onset diabetes of clinical significance in treated hypertensive patients?--Con. 2006 , 8, 126-32	8
352	Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. 2006 , 8, 99-105; quiz 106-7	14

351	More confusing messages from the hypertension treatment trials. 2006 , 8, 8-11	1
350	Is the development of diabetes with antihypertensive therapy a problem?--Pro. 2006 , 8, 120-6	7
349	Drug-induced metabolic syndrome. 2006 , 8, 114-9	24
348	Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. 2006 , 8, 634-41	39
347	Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease. 2006 , 8, 713-20; quiz 721-2	22
346	Managing multiple cardiovascular risk factors: state of the science. 2006 , 8, 12-22	13
345	[The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension]. 2006 , 86, 39-51	22
344	Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. 2006 , 166, 1578-84	22
343	Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2006 , 2006, 62-64	
342	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. 2006 , 24, 1405-12	119
341	European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. 2006 , 24, 2482-5	25
340	The ASCOT trial: a closer look. 2006 , 24, 211-4	1
339	Long-term Effect of Diuretic-based Therapy on Fatal Outcomes in Subjects With Isolated Systolic Hypertension With and Without Diabetes. 2006 , 2006, 67-69	
338	Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. 2006 , 16, 139-47	13
337	European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs. 2006 , 24, 2478-82	6
336	How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. 2006 , 24, 2131-41	103
335	Cost implications of development of diabetes in the ALPINE study. 2006 , 24, S65-72	9
334	New-onset diabetes and antihypertensive drugs. 2006 , 24, 3-10	209

333	Which drug should be used to treat patients with uncomplicated essential hypertension?. 2006 , 15, 303-8	2
332	Antihypertensive therapy in the obese hypertensive patient. 2006 , 15, 487-92	6
331	European Society of Hypertension Scientific Newsletter: control of hypertension in patients with peripheral artery disease. 2006 , 24, 2477-8	1
330	Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. 2006 , 5, 23	29
329	Will ASCOT change the form of anti-hypertensive therapy?. 2006 , 23, 13-4	1
328	Diuretics: a modern day treatment option?. 2006 , 11, 419-27	12
327	Diagnosis and management of hypertension in obesity. 2006 , 7, 155-62	27
326	Pathophysiology of antihypertensive therapy with diuretics. 2006 , 29, 645-53	17
325	Prediabetes and cardiovascular risk in hypertensive patients. 2006 , 8, 97-100	4
324	Metabolic safety of antihypertensive drugs: myth versus reality. 2006 , 8, 403-8	13
323	Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril Study [INVEST]). 2006 , 98, 890-4	58
322	Prevenci3 de la diabetes mellitus en los pacientes con insuficiencia cardiaca. 2006 , 6, 50C-57C	
321	Long-term safety of antihypertensive therapy. 2006 , 49, 16-25	24
320	Obesity and hypertension--the issue is more complex than we thought. 2006 , 21, 264-7	83
319	Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. 2006 , 166, 797-805	29
318	Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes. 2006 , 27, 5-6	6
317	[Blood pressure reduction to lower the risk of stroke]. 2006 , 131 Suppl 5, S135-8	6
316	Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?. 2006 , 15, 323-4	3

315	Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes. 2006 , 17, S141-4		6
314	Thiazide diuretics in the treatment of hypertension: an update. 2006 , 17, S25-9		50
313	Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. <i>Circulation</i> , 2006 , 113, 1588-96	16.7	69
312	Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2006 , 166, 2191-201		193
311	Obesity and Diabetes. 2006 ,		4
310	Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. 2006 , 17, S36-43		31
309	New-onset diabetes mellitus less deadly than elevated blood pressure? Following the evidence in the administration of thiazide diuretics. 2006 , 166, 2174-6		10
308	Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial. <i>Hypertension</i> , 2006 , 47, 10-3	8.5	3
307	Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. 2006 , 29, 2592-7		147
306	The metabolic syndrome: recognition and management. 2006 , 9, 16-33		13
305	Antihypertensive Therapy and the Risk of New-Onset Diabetes. 2006 , 29, 1167-1169		47
304	Surrogate estimates of insulin sensitivity in subjects with hypertension. 2007 , 21, 246-52		6
303	Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. 2007 , 13, 229-39		10
302	Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. 2007 , 21, 374-80		12
301	Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. <i>Hypertension</i> , 2007 , 50, 467-73	8.5	88
300	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. 2007 , 11, 191-205		21
299	Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. 2007 , 72, 1483-92		48
298	[New-onset diabetes mellitus during antihypertensive treatment]. 2007 , 132, 689-95		4

297	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. 2007 , 5, 767-76		12
296	Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. <i>Circulation</i> , 2007 , 115, 2761-88	16.7	557
295	New-onset diabetes, antihypertensive treatment, and outcome. <i>Hypertension</i> , 2007 , 50, 459-60	8.5	17
294	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 25, 1105-87		3825
293	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. <i>Hypertension</i> , 2007 , 50,	8.5	13
292	Will generic hypertension guidelines reduce the proliferation of directives?. 2007 , 93, 775-7		1
291	In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. <i>Hypertension</i> , 2007 , 50, 984-90	8.5	45
290	Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. 2007 , 30, 187-94		18
289	Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?. <i>Current Hypertension Reviews</i> , 2007 , 3, 9-13	2.3	2
288	Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity. 2007 , 4, 163-73		4
287	[Insulin resistance and hypertension]. 2007 , 96, 9-15		
286	Beta-blockers for hypertension. 2007 , CD002003		111
285	Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. 2007 , 71, 144-52		38
284	Antihypertensive medications and risk of diabetes mellitus. 2007 , 16, 256-60		9
283	'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs. 2007 , 22, 335-43		9
282	ESH update on hypertension management. 2007 , 25, 1101; author reply 1101-2		
281	Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. 2007 , 25, 1311-7		88
280	Drug-induced new onset diabetes in hypertension: does it matter?. 2007 , 25, 1201-4		2

- 279 Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?. **2007**, 8, 473-82 2
- 278 Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). **2007**, 2007, 77-79 1
- 277 Antihypertensive Medications and the Risk of Incident Type 2 Diabetes. **2007**, 2007, 36-38
- 276 Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. **2007**, 29, 2667-76 28
- 275 Renin-angiotensin-system blockade in the prevention of diabetes. **2007**, 76 Suppl 1, S13-21 24
- 274 Are we misunderstanding beta-blockers. **2007**, 120, 10-27 66
- 273 Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. **2007**, 369, 201-7 809
- 272 Evoluci3n de la glucemia en pacientes hipertensos con s3ndrome metab3lico, tratados con las combinaciones de trandolapril-verapamilo frente a losart3n-hidroclorotiazida. **2007**, 14, 287
- 271 ¿Una determinada medicaci3n antihipertensiva inicial comporta un menor riesgo de diabetes mellitus?. **2007**, 14, 290
- 270 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). **2007**, 16, 135-232 247
- 269 Effects of antihypertensives on glucose metabolism. **2007**, 5, 211-9 16
- 268 Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension. **2007**, 6, 583-94 3
- 267 Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats. **2007**, 12, 145-52 5
- 266 [ESH/ESC 2007 Guidelines for the management of arterial hypertension]. **2007**, 60, 968.e1-94 29
- 265 Dihydropyridine calcium channel antagonists in the management of hypertension. **2007**, 67, 1309-27 77
- 264 Thiazide diuretics exacerbate fructose-induced metabolic syndrome. **2007**, 18, 2724-31 87
- 263 Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?. **2007**, 3, 8-9 0
- 262 Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. **2007**, 100, 386-92 11

261	Diuretic Therapy in Cardiovascular Disease. 2007 , 213-230	2
260	Insulin Resistance and Diabetes in Hypertension. 2007 , 681-692	2
259	Effect of telmisartan in hypertensive patients with diabetes mellitus. 2007 , 53, 251-256	
258	Hypertension and Diabetes Mellitus. 2007 , 406-417	2
257	. 2007 ,	2
256	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. 2007 , 99, 1E-35E	18
255	Diuretic-induced increase in blood glucose levels: clinical implications. 2007 , 2, 133-5	1
254	Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. 2007 , 50, 197-202	3
253	Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. 2007 , 50, 188-96	4
252	Some thoughts about recent hypertension trials. 2007 , 30, 268-70	
251	Combination pharmacotherapy in hypertension. 2006 , 38, 673-82	2
250	Antihypertensive agents, insulin sensitivity, and new-onset diabetes. 2007 , 7, 191-9	40
249	Insulin resistance and blood pressure. 2008 , 10, 319-25	20
248	First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. 2008 , 7, 22	13
247	Preventing thiazide-induced hyperglycemia: opportunities for clinical pharmacists. 2008 , 28, 1425-8	1
246	Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. 2008 , 3, 18-25	18
245	Using diuretics in practice--one opinion. 2008 , 10, 856-62	14
244	Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. 2008 , 10, 894-903	34

243	Abdominal obesity is associated with potassium depletion and changes in glucose homeostasis during diuretic therapy. 2008 , 10, 443-9	22
242	Ten years and counting: the journal of clinical hypertension. 2008 , 10, 333-40	
241	Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. 2008 , 57, 1278-85	19
240	Prevencci3n primaria farmacol3gica en hipertensi3n arterial y dislipemias. 2008 , 61, 861-879	2
239	S3ndrome metab3lico, enfermedad cardiovascular y medicina sexual. 2008 , 6, 52-61	
238	Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. 2008 , 2, 239-66	15
237	Papel actual de los diur3ticos en el tratamiento de la hipertensi3n arterial. 2008 , 25, 198-204	1
236	Tratamiento de la hipertensi3n en los pacientes diab3ticos. 2008 , 20, 253-258	
235	ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. 2008 , 6, 1195-201	31
234	Use of Drugs in the Primary Prevention of Arterial Hypertension and Dyslipidemia. 2008 , 61, 861-879	
233	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. 2008 , 24, 455-63	36
232	Papel actual de los diur3ticos en el tratamiento de la hipertensi3n arterial. 2008 , 25, 198-204	1
231	The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. 2008 , 15, 1-3	0
230	Is New-Onset Diabetes Mellitus Important?. 2008 , 15, 5-8	1
229	The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk : the pro position. 2008 , 15, 53-7	1
228	EBlockers and Diuretics in the Treatment of Hypertension. 2008 , 15, 109-111	
227	Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. 2008 , 8, 9-14	17
226	New onset diabetes during antihypertensive therapy. 2008 , 21, 493-9	49

225	Hypertension and diabetes. 2008 , 45, 82-106		42
224	Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. 2008 , 31, 1373-83		19
223	Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2008 , 168, 207-17		80
222	The effect of body mass index on fasting blood glucose after initiation of thiazide therapy in hypertensive patients. 2008 , 21, 438-42		10
221	Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. 2008 , 31, 982-8		119
220	Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. 2008 , 36, 80-7		15
219	Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. 2008 , 6, 289-303		10
218	Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. <i>Hypertension</i> , 2008 , 52, 30-6	8.5	91
217	Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. <i>Circulation</i> , 2008 , 117, 2706-15; discussion 2715	16.7	100
216	Randomized study of traditional versus aggressive systolic blood pressure control (Cardio-Sis): rationale, design and characteristics of the study population. 2008 , 22, 243-51		8
215	Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. <i>Circulation</i> , 2008 , 117, 2691-704; discussion 2705	16.7	40
214	Thiazide-induced dysglycemia: it's time to take notice. 2008 , 6, 1291-4		6
213	Middle molecular uremic substances retention itself might influence the bioincompatibility of PD solution. 2008 , 74, 822		1
212	American College of Endocrinology Pre-Diabetes Consensus Conference: part two. 2008 , 31, 2222-9		4
211	Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population. 2008 , 2008, 85-87		
210	Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. 2008 , 2008, 83-85		
209	Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. 2008 , 148, 855-68		114
208	Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. 2008 , 17, 470-6		42

207 Response to thiazide diuretics: rat versus man **2008**, 74, 831

206	Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. 2009 , 5, 361-8	17
205	ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. 2009 , 169, 832-42	81
204	Effects of increasing the dose of pravastatin on serum adiponectin level in Japanese mild hypercholesterolemic and hypertensive patients. 2009 , 59, 445-50	3
203	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. 2009 , 7, 689-702	26
202	Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. 2009 , 32, 617-24	10
201	Combination therapy of angiotensin receptor blocker with statin or thiazolidinediones as promising therapeutic strategy for metabolic syndrome and atherosclerosis. 2009 , 32, 639-40	1
200	Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. 2009 , 10, 168-73	9
199	Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. 2009 , 23, 332-8	7
198	Diuretic-induced potassium depletion and glucose intolerance are not related to hyperactivity of the renin-angiotensin-aldosterone system in hypertensive patients with the metabolic syndrome. 2009 , 11, 549-54	1
197	Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. 2009 , 11, S40-S47	0
196	Cardioprotection with beta-blockers: myths, facts and Pascal's wager. 2009 , 266, 232-41	27
195	Inhibiting the renin-angiotensin system: why and in which patients. 2009 , 21, 66-75	2
194	Risk factor assessment for new onset diabetes: literature review. 2009 , 11, 177-87	27
193	Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?. 2009 , 30, 96-116	356
192	Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex). 2009 , 30, 97-101	9
191	Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. 2009 , 53, S28-34	37
190	Beta-adrenergic antagonists in hypertension: a review of the evidence. 2009 , 43, 2031-43	13

189	Glucose and non-glucose predictors of future onset of type 2 diabetes in newly diagnosed essential hypertensives. 2009 , 72, 564-72	
188	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. 2009 , 25, 279-86	57
187	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. 2009 , 27, 1493-501	34
186	Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. 2009 , 2009, 44-46	
185	Antihypertensive treatment and risk of cardiovascular complications: is the cure worse than the disease?. 2009 , 27, 221-3	10
184	The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. 2010 , 8, 792-803	11
183	Potential by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. 2010 , 28, 340-52	47
182	Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. 2010 , 53, 180-91	64
181	Are there benefits of antihypertensive therapy beyond blood pressure lowering?. 2010 , 12, 440-7	4
180	Diuretics and diabetes incidence--an appeal against the reluctance to prescribe a medication that is safe and proven. 2010 , 27, 130-5	3
179	Methodological Considerations for the Examination of Complex Systems in Aging. 2010 , 30, 35-56	3
178	The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. 2010 , 8, 79-84	8
177	Lipid-lowering agents and new onset diabetes mellitus. 2010 , 11, 1965-70	12
176	Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. 2010 , 33, 1122-7	43
175	Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients. 2010 , 19, 110-8	5
174	Hypertensive treatment in patients with metabolic syndrome. 2010 , 8, 95-104	4
173	Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. 2010 , 403, 258-63	24
172	2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. 2010 , 109, 740-73	72

171	Healthy weight - healthy blood pressure. 2010 , 26, 259-60	7
170	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. 2010 , 17, 73-102	9
169	Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. 2011 , 27, 799-807	13
168	Management issues in hypertensive diabetics. 2011 , 53, 144-148	
167	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Cardiology, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 123, 2434-506	325
166	Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. 2011 , 27, e1-e33	116
165	Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor- α dependent activity. 2011 , 410, 508-13	29
164	Short-term metabolic changes achieved by weight loss in hypertensive patients. 2011 , 153, 286-90	3
163	Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients. 2011 , 2, 490-6	2
162	New-onset diabetes and cardiovascular events in essential hypertensives: a 6-year follow-up study. 2011 , 153, 154-8	6
161	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 123, 2434-506	100
160	Management of Hypertension among Patients with Coronary Heart Disease. 2011 , 2011, 653903	11
159	Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β cells. 2011 , 48, 237-44	56
158	Impact of concomitant diabetes and chronic kidney disease on preload-induced changes in left ventricular diastolic filling in hypertensive patients. 2011 , 29, 144-53	7
157	Why are we still using hydrochlorothiazide?. 2011 , 13, 867-9	7
156	What is the blood pressure goal for the elder patient 75 years of age or older?. 2011 , 13, 485-91	2
155	Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). 2011 , 34, 1295-301	12
154	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i> , 2011 , 123, 2434-506	16.7 255

153	Diuretic treatment of hypertension. 2011 , 34 Suppl 2, S313-9		32
152	The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors. 2011 , 25, 343-5		1
151	Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension. 2011 , 27, 809-19		19
150	Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate. 2012 , 8, 133-4		17
149	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. 2012 , 63, 358-66		21
148	Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. 2012 , 6, 555-63		7
147	Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. <i>Hypertension</i> , 2012 , 59, 1104-9	8.5	106
146	Beta-blockers for hypertension. 2012 , CD002003		21
145	Effects of renal denervation on insulin resistance. 2012 , 10, 1381-6		9
144	Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. 2012 , 25, 704-10		15
143	Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control?. 2012 , 18, 1011-20		7
142	Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors. 2012 , 30, 188-93		19
141	A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications. <i>Current Hypertension Reviews</i> , 2012 , 8, 196-226	2.3	2
140	Effects of valsartan on cardiovascular morbidity and mortality in high-risk hypertensive patients with new-onset diabetes mellitus. 2012 ,		0
139	What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. 2012 , 28 Suppl 2, 60-6		7
138	Short-term effects of eicosapentaenoic acid on P wave signal-averaged electrocardiogram in patients with coronary artery disease. 2012 , 154, 200-2		1
137	Hypertensive crisis: comparison between diabetics and non-diabetics. 2012 , 154, 198-200		6
136	Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving β arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction. 2012 , 153, 2985-96		27

135	Beta-blockers for hypertension. 2012 , 11, CD002003	69
134	Antihypertensive Therapy and New-Onset Diabetes. 2012 , 121-127	
133	Hypertension in the elderly. 2012 , 6, 285-294	1
132	Diabetes and Hypertension. 2012 ,	0
131	Hypertension in the elderly. 2012 ,	1
130	The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. 2012 , 8, 6-10	3
129	Should two-drug initial therapy for hypertension be recommended for all patients?. 2012 , 14, 324-32	8
128	Guidelines for use of diuretics: a view from a member of JNC 7. 2012 , 14, 273-6	3
127	Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. 2012 , 11, 1	36
126	Diphenyl diselenide supplementation reduces biochemical alterations associated with oxidative stress in rats fed with fructose and hydrochlorothiazide. 2013 , 204, 191-9	17
125	Impaired fasting glucose in hypertensive patients: prevalence and cross-sectional analysis of associations with cardiovascular disease. 2013 , 15, 475-80	2
124	Diuretic Therapy in Cardiovascular Disease. 2013 , 160-171	
123	Diferencias y similitudes entre diuréticos. 2013 , 30, 13-19	1
122	[Vascular risk in outpatient from Internal Medicine departments. MICARE Study]. 2013 , 140, 246-54	7
121	Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. 2013 , 106, 721-9	40
120	The effect of carvedilol on blood glucose levels in normal albino rats. 2013 , 7, 1900-3	2
119	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. 2013 , 23, 697-705	12
118	Association of electrocardiographically determined left ventricular mass with incident diabetes, 1985-1986 to 2010-2011: Coronary Artery Risk Development in Young Adults (CARDIA) study. 2013 , 36, 645-7	4

117	Metabolic impact of adding a thiazide diuretic to captopril. <i>Hypertension</i> , 2013 , 61, 765-6	8.5
116	A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic. 2013 , 83, 1076-86	39
115	In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. 2013 , 30, 1189-97	12
114	Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. 2013 , 62, 3547-52	22
113	Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. 2013 , 13, 430-6	13
112	The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study. 2013 , 3, e003475	16
111	Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. 2014 , 14, 35-40	31
110	Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats. 2014 , 36, 159-64	4
109	Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. 2014 , 34, 1132-40	8
108	Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study. 2014 , 27, 199-206	16
107	Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. 2014 , 15, 527-47	47
106	Hypertension in Diabetes Mellitus. 2014 , 119-134	
105	Diabetes and Kidney Disease. 2014 ,	0
104	Thiazide diuretic prophylaxis for kidney stones and the risk of diabetes mellitus. 2014 , 192, 1700-4	11
103	Statins and the risk of diabetes: evidence from a large population-based cohort study. 2014 , 37, 2225-32	72
102	Antihypertensive drugs and glucose metabolism. 2014 , 6, 517-30	51
101	G-protein-coupled receptor kinase 2 and endothelial dysfunction: molecular insights and pathophysiological mechanisms. 2015 , 51, 37-49	12
100	Problems of using Hydrochlorothiazide Diuretic in Adult Diabetic Patient in Diabetic Clinic of Adama Hospital Medical College, East Shoa Zone, Oromia Regional State, Ethiopia. 2015 , 04,	

99	Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure. 2015 , 73-118		
98	Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. 2015 , 157-179		
97	Use of Calcium Channel Blockers is Associated with Mortality in Patients with Chronic Kidney Disease. 2015 , 40, 630-7		5
96	2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. 2015 , 78, 1-47		140
95	New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. 2015 , 64, 471-5		19
94	Diuretics for the Treatment of Hypertension. 2015 , 823-851		
93	Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders. 2015 , 13, 23-31		5
92	Antidiabetic effect of green rooibos (<i>Aspalathus linearis</i>) extract in cultured cells and type 2 diabetic model KK-A(y) mice. 2015 , 67, 699-710		39
91	Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 9, 453-98		39
90	Spinal NF-B and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. 2015 , 10, e0115120		26
89	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Hypertension</i> , 2015 , 65, 1372-407	8.5	76
88	Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1998-2038		97
87	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Circulation</i> , 2015 , 131, e435-70	16.7	80
86	Drug-Induced Hyperglycaemia and Diabetes. 2015 , 38, 1153-68		72
85	ACEi and ARBS in Hypertension and Heart Failure. 2015 ,		1
84	Diuretics. 2016 , 1030-1053		
83	Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism. 2016 , 99, 390-400		21
82	Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. 2016 , 80, 2277-2281		38

81	Hypertension, diabetes and blood pressure targets: ongoing challenges. 2016 , 5, 120-121	
80	Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. 2016 , 10, 271-8	41
79	Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. 2016 , 37, 968-74	10
78	New-onset diabetes in hypertensive patients and mortality: timing is everything. 2016 , 37, 975-7	4
77	Type 2 Diabetes. 2016 ,	2
76	Beta-blockers for hypertension. 2017 , 1, CD002003	69
75	Glucose homeostasis abnormalities among Cameroon patients with newly diagnosed hypertension. 2017 , 19, 519-523	5
74	Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?. 2017 , 12, 90-98	3
73	THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. 2017 , 23, 363-371	3
72	Treatments for diabetes mellitus type II: New perspectives regarding the possible role of calcium and cAMP interaction. 2018 , 830, 9-16	11
71	Clinical features and therapeutic perspectives on hypertension in diabetics. 2018 , 41, 213-229	11
70	Genome Wide Association Study Identifies the Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. 2018 , 7,	8
69	Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. 2018 , 18, 106-112	3
68	Impact of Drugs on Diabetes Risk and Glycemic Control. <i>Endocrinology</i> , 2018 , 1-33	0.1
67	Comparison of real-world effectiveness between valsartan and non-RAS inhibitor monotherapy on the incidence of new diabetes in Chinese hypertensive patients: An electronic health recording system based study. 2019 , 41, 244-254	3
66	Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism Is Not Responsible for Antihypertensive Therapy Induced New Onset of Type 2 Diabetes in Essential Hypertension. 2019 , 12, 1179551418825037	2
65	Adverse Metabolic Effects of Diltiazem Treatment During Diabetic Cardiomyopathy. 2019 , 24, 193-203	1
64	Hypertension in Metabolic Syndrome: Novel Insights. <i>Current Hypertension Reviews</i> , 2020 , 16, 12-18	2.3 14

63	A thienopyridine, CB-20, exerts diuretic activity by inhibiting urea transporters. 2020 , 41, 65-72		8
62	The Efficacy effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. 2020 , 57, 117-131		3
61	Hypertension and type 2 diabetes: lights and shadows about causality. 2020 , 34, 91-93		12
60	Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials. 2020 , 35, 1849-1860		1
59	Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study). 2020 , 18, 110-118		0
58	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020 , 141, e779-e806	16.7	58
57	[The use of diuretics in chronic heart failure. Position paper of the Russian Heart Failure Society]. <i>Kardiologiya</i> , 2021 , 60, 13-47	1.5	5
56	The Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) Study. <i>Panminerva Medica</i> , 2021 ,		2
55	Joint Predictors of Hypertension and Type 2 Diabetes Among Adults Under Treatment in Amhara Region (North-Western Ethiopia). <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 2453-2463	3.4	
54	New-Onset Diabetes, Endothelial Dysfunction, and Cardiovascular Outcomes in Hypertensive Patients: An Illness-Event Model Analysis. <i>Biomedicines</i> , 2021 , 9,	4.8	0
53	Discordances between pediatric and adult thresholds in the diagnosis of hypertension in adolescents with CKD. <i>Pediatric Nephrology</i> , 2021 , 1	3.2	1
52	Fixed Low-Dose Antihypertensive Therapy. 2007 , 1061-1073		2
51	Hypertension and Diabetes. 2007 , 417-436		0
50	[Effects of antihypertensive drugs on glucose metabolism and cardiovascular events]. <i>Tidsskrift for Den Norske Laegeforening</i> , 2009 , 129, 1740-4	3.5	1
49	Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K (K) Channels. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
48	Diuretics. 2006 , 1152-1169		
47	The antidiabetic effect of angiotensin II receptor antagonists. 2006 , 85-98		
46	Atherosclerosis: Pathogenesis, Morphology, and Risk Factors. 2007 , 1593-1613		

45 Preface. **2007**, xv-xvii

44 Diuretiki pri arterial'noy gipertenzii: vse li problemy resheny?. *Systemic Hypertension*, **2007**, 4, 48-55 1.6

43 Diuretics in the treatment of hypertension and the risk of new-onset diabetes. *Cor Et Vasa*, **2007**, 49, 362-367 0.3

42 Antihypertonika. **2008**, 361-377

41 The changing strategies of antihypertensive treatment in metabolic syndrome: From drugs of choice towards an optimal therapeutic combination. *Arterial Hypertension (Russian Federation)*, **2008**, 14, 65-70 0.7

40 Safe combination therapy in patients with hypertension and metabolic syndrome: the STAR-LET study. *Arterial Hypertension (Russian Federation)*, **2008**, 14, 391-396 0.7

39 CB1 Antagonism in the Management of Abdominal Obesity. **2008**, 223-232

38 DIURETICS. **2009**, 197-261

37 ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS. **2009**, 571-691

36 Antihypertonika. **2009**, 363-380

35 Antihypertonika. **2010**, 389-408

34 Antihypertonika. **2011**, 401-420

33 Dilemma in Diabetes Care Relates to Its Complications: Strategies for Prevention. *Journal of Diabetes Research & Clinical Metabolism*, **2012**, 1, 15 0

32 Antihypertonika. **2012**, 403-424

31 Carbohydrate metabolism parameters in angina patients treated with metoprolol and its combination with trimetazidine. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2012**, 11, 10-15 0.9

30 Antihypertonika. **2013**, 391-412

29 Antihypertonika. **2014**, 445-468

28 Antihypertonika. **2015**, 451-475

27	Antihypertonika. 2016 , 335-350		
26	[Controlled diuretic monotherapy in hypertensive patients: Efficiency and metabolic safety]. <i>Terapevticheskii Arkhiv</i> , 2016 , 88, 59-64	0.9	1
25	Antihypertonika. 2017 , 335-351		
24	Impact of Drugs on Diabetes Risk and Glycemic Control. <i>Endocrinology</i> , 2018 , 541-573	0.1	0
23	Antihypertonika. 2018 , 385-400		
22	Antihypertonika. 2019 , 513-529		
21	Impact of Drugs on Diabetes Risk and Glycemic Control. <i>Endocrinology</i> , 2019 , 1-33	0.1	0
20	Alpha Adducin (ADD1) Gene Polymorphism and New Onset of Diabetes Under the Influence of Selective Antihypertensive Therapy in Essential Hypertension. <i>Current Hypertension Reviews</i> , 2019 , 15, 123-134	2.3	1
19	How to treat arterial hypertension in obese patients?. <i>Vnitřni Lekarství</i> , 2020 , 66, 490-493	0.3	
18	Impact of Drugs on Diabetes Risk and Glycemic Control. <i>Endocrinology</i> , 2020 , 541-573	0.1	
17	Antihypertonika. 2020 , 379-394		
16	Diuretics and Adrenergic Blockers in the Management of Hypertension in the Elderly. 2005 , 297-319		
15	Obesity, Diabetes, and Hypertension. 2006 , 169-192		1
14	Antihypertonika. 2007 , 408-424		
13	Antihypertonika. 2008 , 369-385		
12	Treating to protect: current cardiovascular treatment approaches and remaining needs. <i>Medscape Journal of Medicine</i> , 2008 , 10 Suppl, S3		1
11	Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia. <i>International Journal of Health Sciences</i> , 2017 , 11, 38-44	1.1	1
10	Dapagliflozin Induces Vasodilation in Resistance-Size Mesenteric Arteries by Stimulating Smooth Muscle Cell K v7 Ion Channels. <i>SSRN Electronic Journal</i> ,	1	

9	Antihypertonika. 2021 , 283-297		
8	Hypertension and Diabetes. 2022 , 263-291		1
7	Interaction of Hypertension and Insulin Resistance Exacerbates the Occurrence of Diabetes Mellitus in Healthy Individuals.. <i>Journal of Diabetes Research</i> , 2022 , 2022, 9289812	3.9	0
6	Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 469-75	3.1	19
5	Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels. <i>Heliyon</i> , 2022 , 8, e09503	3.6	0
4	Polypharmacology in Clinical Applications: Renal Polypharmacology. 2022 , 323-342		0
3	Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure. 2022 , 150, 211-222		0
2	Arterielle Hypertonie. 2022 , 155-204		0
1	Risk Factors Associated With Hypertension in Young Adults: A Systematic Review. 2023 ,		0